iTeos and GSK Show Promising Anti-TIGIT Results in Lung Cancer Study at ESMO 2024

Sep 14, 2024, 06:32 AM

iTeos Therapeutics and GSK have announced promising results from their mid-stage GALAXIES Lung-201 study, which investigates the combination of Belrestotug and Dostarlimab in first-line, PD-L1 high non-small cell lung cancer patients. The study, presented at the European Society for Medical Oncology (ESMO) 2024 conference, showed a clinically meaningful objective response rate at every dose level in a follow-up interim analysis. This development has renewed cautious optimism around anti-TIGIT immunotherapy drugs, which have faced setbacks in the past. The positive response rates suggest that TIGIT could be a viable target for lung cancer treatment.